DE68902300T2 - Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. - Google Patents
Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure.Info
- Publication number
- DE68902300T2 DE68902300T2 DE8989311021T DE68902300T DE68902300T2 DE 68902300 T2 DE68902300 T2 DE 68902300T2 DE 8989311021 T DE8989311021 T DE 8989311021T DE 68902300 T DE68902300 T DE 68902300T DE 68902300 T2 DE68902300 T2 DE 68902300T2
- Authority
- DE
- Germany
- Prior art keywords
- solution
- acid
- active ingredient
- salbutamol
- solution according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 title claims description 8
- 229960002052 salbutamol Drugs 0.000 title claims description 8
- 239000002253 acid Substances 0.000 title description 4
- 239000003186 pharmaceutical solution Substances 0.000 title description 3
- 239000000243 solution Substances 0.000 claims description 61
- 239000004480 active ingredient Substances 0.000 claims description 23
- 229960000265 cromoglicic acid Drugs 0.000 claims description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- BNPSSFBOAGDEEL-UHFFFAOYSA-N albuterol sulfate Chemical group OS(O)(=O)=O.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1.CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 BNPSSFBOAGDEEL-UHFFFAOYSA-N 0.000 claims description 9
- 239000003002 pH adjusting agent Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 229960001361 ipratropium bromide Drugs 0.000 claims description 3
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 claims description 3
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 claims 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- -1 acetic acid Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000002663 nebulization Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 206010006440 Bronchial obstruction Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical class NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB888825892A GB8825892D0 (en) | 1988-11-04 | 1988-11-04 | Pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE68902300D1 DE68902300D1 (de) | 1992-09-03 |
| DE68902300T2 true DE68902300T2 (de) | 1993-02-11 |
Family
ID=10646341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE8989311021T Expired - Fee Related DE68902300T2 (de) | 1988-11-04 | 1989-10-25 | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0370632B1 (enExample) |
| JP (1) | JPH02196716A (enExample) |
| AU (1) | AU620932B2 (enExample) |
| BE (1) | BE1002239A5 (enExample) |
| CA (1) | CA2002190A1 (enExample) |
| CH (1) | CH680191A5 (enExample) |
| DE (1) | DE68902300T2 (enExample) |
| DK (1) | DK548689A (enExample) |
| ES (1) | ES2023727A6 (enExample) |
| FR (1) | FR2638640B1 (enExample) |
| GB (2) | GB8825892D0 (enExample) |
| GR (1) | GR1000308B (enExample) |
| IE (1) | IE63433B1 (enExample) |
| IL (1) | IL92173A (enExample) |
| IT (1) | IT1239282B (enExample) |
| LU (1) | LU87615A1 (enExample) |
| NZ (1) | NZ231245A (enExample) |
| PT (1) | PT92188B (enExample) |
| ZA (1) | ZA898323B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4132176C2 (de) * | 1991-09-27 | 1997-03-13 | Ig Spruehtechnik Gmbh | Dosieraerosole mit Isobutan als Treibmittel |
| IT1265647B1 (it) * | 1992-11-18 | 1996-11-22 | Farmin Srl | Composizione farmaceutiche topiche per le allergie respiratorie |
| GB9317752D0 (en) * | 1993-08-26 | 1993-10-13 | Fisons Plc | New pharmaceutical use |
| US20030215396A1 (en) | 1999-09-15 | 2003-11-20 | Boehringer Ingelheim Pharma Kg | Method for the production of propellant gas-free aerosols from aqueous medicament preparations |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| JP2002017857A (ja) * | 2000-06-26 | 2002-01-22 | Ruian Pharmaceutic Co Ltd | 投薬制御方法 |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US6702997B2 (en) * | 2001-10-26 | 2004-03-09 | Dey, L.P. | Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| JP2006513129A (ja) * | 2001-10-26 | 2006-04-20 | デイ エルピー | 小児喘息の症状を緩和するためのアルブテロール吸入溶液、システム、キット及び方法 |
| AU2006202584B2 (en) * | 2001-10-26 | 2009-11-26 | Mylan Specialty L.P. | An albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| GB0406069D0 (en) * | 2004-03-17 | 2004-04-21 | Thompson James | Process |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3957965A (en) * | 1967-08-08 | 1976-05-18 | Fisons Limited | Sodium chromoglycate inhalation medicament |
| JPH0662601B2 (ja) * | 1985-08-16 | 1994-08-17 | 京都薬品工業株式会社 | クロモグリク酸誘導体および抗アレルギ−剤 |
-
1988
- 1988-11-04 GB GB888825892A patent/GB8825892D0/en active Pending
-
1989
- 1989-10-25 DE DE8989311021T patent/DE68902300T2/de not_active Expired - Fee Related
- 1989-10-25 GB GB8924052A patent/GB2224932B/en not_active Expired - Fee Related
- 1989-10-25 EP EP89311021A patent/EP0370632B1/en not_active Expired - Lifetime
- 1989-10-30 LU LU87615A patent/LU87615A1/fr unknown
- 1989-10-31 IL IL92173A patent/IL92173A/xx not_active IP Right Cessation
- 1989-10-31 BE BE8901159A patent/BE1002239A5/fr not_active IP Right Cessation
- 1989-10-31 IT IT22216A patent/IT1239282B/it active IP Right Grant
- 1989-11-01 ZA ZA898323A patent/ZA898323B/xx unknown
- 1989-11-01 AU AU43964/89A patent/AU620932B2/en not_active Ceased
- 1989-11-02 GR GR890100726A patent/GR1000308B/el unknown
- 1989-11-02 JP JP1285091A patent/JPH02196716A/ja active Pending
- 1989-11-02 CH CH3962/89A patent/CH680191A5/fr not_active IP Right Cessation
- 1989-11-02 NZ NZ231245A patent/NZ231245A/en unknown
- 1989-11-03 ES ES8903735A patent/ES2023727A6/es not_active Expired - Fee Related
- 1989-11-03 DK DK548689A patent/DK548689A/da not_active Application Discontinuation
- 1989-11-03 PT PT92188A patent/PT92188B/pt active IP Right Grant
- 1989-11-03 FR FR8914451A patent/FR2638640B1/fr not_active Expired - Fee Related
- 1989-11-03 CA CA002002190A patent/CA2002190A1/en active Pending
- 1989-11-03 IE IE355089A patent/IE63433B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ231245A (en) | 1990-12-21 |
| AU620932B2 (en) | 1992-02-27 |
| GB8924052D0 (en) | 1989-12-13 |
| GB2224932A (en) | 1990-05-23 |
| FR2638640B1 (fr) | 1993-11-26 |
| GR1000308B (el) | 1992-05-12 |
| IE893550L (en) | 1990-05-04 |
| EP0370632B1 (en) | 1992-07-29 |
| IL92173A0 (en) | 1990-07-12 |
| IL92173A (en) | 1993-05-13 |
| BE1002239A5 (fr) | 1990-10-30 |
| IT8922216A0 (it) | 1989-10-31 |
| FR2638640A1 (fr) | 1990-05-11 |
| IT8922216A1 (it) | 1991-05-01 |
| GB8825892D0 (en) | 1988-12-07 |
| AU4396489A (en) | 1990-05-10 |
| EP0370632A1 (en) | 1990-05-30 |
| IT1239282B (it) | 1993-10-19 |
| DK548689A (da) | 1990-05-05 |
| DK548689D0 (da) | 1989-11-03 |
| ES2023727A6 (es) | 1992-02-01 |
| JPH02196716A (ja) | 1990-08-03 |
| LU87615A1 (fr) | 1991-05-07 |
| IE63433B1 (en) | 1995-04-19 |
| PT92188B (pt) | 1996-01-31 |
| PT92188A (pt) | 1990-05-31 |
| CA2002190A1 (en) | 1990-05-04 |
| GR890100726A (en) | 1990-12-31 |
| ZA898323B (en) | 1990-07-25 |
| GB2224932B (en) | 1992-01-02 |
| DE68902300D1 (de) | 1992-09-03 |
| CH680191A5 (enExample) | 1992-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69108200T2 (de) | 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1). | |
| DE69511374T2 (de) | Neue und verbesserte aminoglykosidformulierung als aerosol | |
| DE68902649T2 (de) | Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen. | |
| DE69024672T2 (de) | Sprays zur Behandlung von Infektionen des Tractus Respiratorius | |
| EP1255557B1 (de) | Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung enthaltend desmopressin | |
| DE69920201T2 (de) | Zusammensetzungen enthaltend glykolderivate, alkohole und vitamin d | |
| DE68902300T2 (de) | Pharmazeutische loesung enthaltend salbutamol und cromoglycinsaeure. | |
| DE2708152B2 (de) | Pharmazeutisches Trägermaterial für die örtliche Aufbringung auf Schleimhäuten | |
| CH662945A5 (de) | Ophthalmische loesung. | |
| DE69033112T2 (de) | Zink enthaltende Sprays | |
| EP0243308A2 (de) | Stabilisierung des Konservierungsmittels Thiomersal in Augenarzneimitteln | |
| EP2766008B1 (de) | Zusammensetzung für die nasale applikation mit verbesserter stabilität | |
| WO2001078732A1 (de) | Lagerstabile infusionslösung des ciprofloxacins | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| DE69300017T2 (de) | Wässrige pharmazeutische Zubereitung von Natriumcromoglykat. | |
| DE60003183T2 (de) | Formulierungen von steroidlösungen zur inhalativen verabreichung | |
| DE60101979T2 (de) | Lösung enthaltend N-[O-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glyzin Mononatriumsalz Tetrahydrat und diese Lösung enthaltendes Arzneimittel | |
| DE68915203T2 (de) | Pharmazeutische Mischungen. | |
| DE3324964C2 (enExample) | ||
| DE3787274T2 (de) | Pharmazeutische Präparate, die eine wässerige Lösung eines Pyranoquinolins enthalten. | |
| DE3700379C2 (enExample) | ||
| DE3852717T2 (de) | Zusammensetzung für die Prophylaxe von Pneumocystis-carinii-Pneumonie. | |
| EP1320368A1 (de) | Lagerstabile infusionslösung des ciprofloxacins mit verringertem säuregehalt | |
| EP1001756A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| EP0591710A1 (de) | Mesna-Injektionslösungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |